Benzinga | Aug 3, 2021 04:13PM EDT

Jazz Pharmaceuticals Q2 EPS $3.90 Beats $3.42 Estimate, Sales $751.81M Beat $735.62M Estimate

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported quarterly earnings of $3.90 per share which beat the analyst consensus estimate of $3.42 by 14.04 percent. This is a 5.12 percent increase over earnings of $3.71 per share from the same period last year. The company reported quarterly sales of $751.81 million which beat the analyst consensus estimate of $735.62 million by 2.20 percent. This is a 33.67 percent increase over sales of $562.44 million the same period last year.